

PRIOR AUTHORIZATION REQUEST

Orladeyo

| Patient I | nformation: | 1 • | | | |
|---------------------------------------|--|-----------------------------------|---|---|---------------------------------------|
| Name: | | | | | |
| Member | ID: | | | | |
| Address | <u> </u> | | | | |
| City, Sta | | | | | |
| Date of E | 3irth: | | | | |
| Prescrib | er Informati | ion: | | | |
| Name: | | 10 | | | |
| NPI: | | | | | |
| Phone N | umber: | | | | |
| Fax Num | | | | | |
| Address | | | | | |
| City, Sta | | | | | |
| | | | | | |
| Request | ed Medicati | on | | | |
| Rx Name: | | | | | |
| Rx Strength | | | | | |
| Rx Quar | ıtity: | | | | |
| Rx Frequ | | | | | |
| Rx Route | | | | | |
| Administ | | | | | |
| Diagnosi | is and ICD Co | ode: | | | |
| prescribed quantities Upon rece | a medication can be provided by the color of | for your ed. Pleas empleted | fit requires that we review certain requests for coverage with the properties provided that requires Prior Authorization before benefit coverage or consecutive the following questions then fax this form to the toll-free reports form, prescription benefit coverage will be determined based of the that supporting clinical documentation is required. | overage of number lise on the pla | f addition sted belov an's rule |
| 1 | prophylaxis (It | angioede f checke | ema (HAE) due to C1 inhibitor (C1-INH) deficiency [Type I or Type II], | | |
| 2 | Is the patient | | er than or equal to 12 year(s) of age? estions.] | Yes | No |
| 3 | Is the patient | | ntly receiving Orladeyo for HAE type I or type II prophylaxis? tion 6.] | Yes | No |

Yes

No

Is documentation being provided to confirm that the patient has low levels of

PRIOR AUTHORIZATION REQUEST

| | functional C1-INH protein (less than 50% of normal) at baseline, as defined by the laboratory reference values? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] | | |
|---|---|-----|----|
| 5 | Is documentation being provided to confirm that the patient has lower than normal serum C4 levels at baseline, as defined by the laboratory reference values? ACTION REQUIRED: Submit supporting documentation. [If yes, skip to question 8.] [If no, no further questions.] | Yes | No |
| 6 | Is documentation being provided to confirm the patient's HAE type I or type II diagnosis? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] | Yes | No |
| 7 | According to the prescriber, has the patient had a favorable clinical response since initiating Orladeyo prophylactic therapy compared with baseline (that is, prior to initiating prophylactic therapy)? [Note: Examples of favorable clinical response include decrease in HAE acute attack frequency, decrease in HAE attack severity, or decrease in duration of HAE attacks.] [If no, no further questions.] | Yes | No |
| 8 | Is the requested medication being prescribed by or in consultation with an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders? [If no, no further questions.] | Yes | No |
| 9 | Will the requested medication be taken in combination with other HAE PROPHYLACTIC therapies (for example, Cinryze, Haegarda, Takhzyro)? [Note: Patients may use other medications, including Cinryze, for ACUTE treatment of HAE attacks, and for short- term (procedural) prophylaxis.] | Yes | No |

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B: Physician Signature



PRIOR AUTHORIZATION REQUEST

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.